Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • Immune Reconstitution Following CD7 CAR-T Therapy for Relapsed/Refractory Acute T-cell Lymphoblastic Leukemia/T-cell Lymphoblastic Lymphoma

    From June 13 to 16, 2024, the 29th Annual Congress of the European Hematology Association (EHA) was held in Madrid, Spain. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars from around the world every year to share and discuss innovative ideas and the latest scientific and…

    2024.07.01
  • EHA in 5 Minutes | Professor Huanling Zhu: SUSTRENIM Trial— Observational Study on Sustained Deep Molecular Response and Treatment-Free Remission

    The 29th Annual Meeting of the European Hematology Association (EHA) was held from June 13-16, 2024, in Madrid, Spain. As the largest international event in the field of hematology in Europe, this conference attracts numerous renowned experts and scholars from around the world to share and discuss innovative concepts, the latest scientific research, and clinical…

    2024.07.01
  • ASCO 2024丨mRNA-4157 Vaccine Shows Long-Term Survival Benefits in Melanoma Treatment

    mRNA cancer vaccines are an emerging cancer treatment strategy that uses mRNA technology to encode tumor-associated antigens, stimulating the patient’s immune system to fight cancer cells. With the successful application of mRNA technology in vaccine development, its role in cancer treatment is gaining increasing attention. mRNA-4157 is a novel personalized cancer vaccine that has shown…

    2024.06.30
  • ASCO 2024丨Impact of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

    The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 31 to June 4. Multiple research advancements in urologic oncology were presented, including the SWOG S1600 study results shared by Dr. Jill Hamilton-Reeves. This study explored the impact of immune-enhancing nutrition on the outcomes of radical cystectomy. Oncology Frontier…

    2024.06.29
  • JOH | Changes in Liver Stiffness Measurements Independently Associated with Liver-Related Events Risk in NAFLD Patients

    Recently, Professor Naga P. Chalasani and his research team from Indiana University published a significant study online in the prestigious hepatology journal JOH. The study, titled “Increases and Decreases in Liver Stiffness Measurements are Independently Associated with the Risk of Liver-Related Events in NAFLD Patients,” was initiated by Professor Naga P. Chalasani in collaboration with…

    2024.06.29
  • ASCO 2024丨Liver Cancer Research Highlights: First-Line Immunotherapy “Double Star” Post-Immunotherapy Targeted Treatment, and CAR-T Therapy for Liver Cancer

    The treatment of advanced hepatocellular carcinoma (HCC) has entered the era of targeted and immunotherapy, with combined regimens becoming the first-line standard. More combination therapies are still under exploration. At the recently concluded 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the CheckMate 9DW study announced positive results for the dual immunotherapy of anti-PD-L1…

    2024.06.29
  • ASCO International Perspective | Christos Kyriakopoulos: Results of the CHAARTED2 Study on Cabazitaxel Combined with Abiraterone for mCRPC

    The CHAARTED study demonstrated that early use of chemotherapy combined with androgen deprivation therapy (ADT+docetaxel) significantly improves survival for most patients with metastatic hormone-sensitive prostate cancer (HSPC). However, most patients eventually develop castration-resistant prostate cancer (CRPC) and require additional systemic treatment. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Christos Kyriakopoulos…

    2024.06.28
  • ASCO International Perspective | Professor Jill Hamilton Reeves: Can Enhanced Immunonutrition Improve Outcomes for Radical Cystectomy Patients?

    The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was held from May 31 to June 4 in Chicago, on the shores of Lake Michigan. Professor Jill Hamilton Reeves from the University of Kansas Medical Center shared the results of the SWOG S1600 study at the conference, exploring the impact of immunonutrition on the…

    2024.06.28
«previous next»
Recent Posts
  • CSCO 2026 | Professor Xinghao Ai: Obrixtamig Plus First-Line Standard Therapy Shows Encouraging Efficacy in Extensive-Stage Small Cell Lung Cancer
  • CSCO 2026 | Professor Yanxia Shi: Extending Endocrine-Based Treatment — CDK2/4/6 Inhibition Offers a Therapeutic Option for Mutation-Negative Patients After CDK4/6 Inhibitor Therapy
  • CSCO 2026 | Professor Biyun Wang: From Stratification to Precision — Treatment Strategies After CDK4/6 Inhibitor Resistance and the Clinical Positioning of the CDK2/4/6 Inhibitor Kermoxili
  • CSCO International Perspectives | Professor Kun Wang in Conversation With Professor Pier Paolo Berton Giachetti: From Experience to Evidence — The Path Toward Precision Treatment in Early HER2-Positive Breast Cancer
  • ESMO Preview | Professor Yongmei Yin: A New Breakthrough in HR+/HER2− Advanced Breast Cancer — Iza-bren Ushers in a New Era of Bispecific ADC Therapy
Recent Comments
    Archives
    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top